Total Facility Solutions wins contract from Novartis

Published: 14-Sep-2011
Manufacturing Finance

To install hygienic process piping at Vaccines and Diagnostics plant in Holly Springs, NC

Total Facility Solutions wins contract from Novartis
Total Facility Solutions, a specialist contractor focused on critical process infrastructure, has been awarded a contract to install hygienic process piping at the Novartis Vaccines and Diagnostics campus in Holly Springs, North Carolina, US.

The order is part of Novartis’ US$36m expansion of its pandemic and seasonal flu production facility, announced last December, which will create 100 new jobs at the Holly Springs development lab and pilot plant.

‘This selection to fabricate and install process piping at Novartis affirms the strength of our model for serving the life science business,’ said Joe Cestari, president of Total Facility Solutions.

‘Having invested heavily in our own North Carolina facility in 2009, we bring the infrastructure, industry expertise and experienced personnel necessary to execute on this project on time, on budget and to specification.’

The project will be operated out of Total Facility Solutions’ Raleigh, NC location, using its 4,000ft2 clean manufacturing space to complete all building work. This plant is equipped with the latest technology for orbital welding and meets stringent market requirements while facilitating just-in-time delivery to the construction site. Bovis Lend Lease and Novartis’ project managers are overseeing the project.

Total Facility Solutions (TFS) provides turnkey facilities contracting services including high-purity piping, gas and chemical systems, ultra-high purity water systems, tool and equipment installation, clean utilities, and electrical services to the semiconductor, electronics, nanotechnology, photovoltaic, life sciences, mission critical, and renewable energy industries.

See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Containment
Clean environments: meeting modern drug production challenges

Clean environments: meeting modern drug production challenges

Read more
New medicinal therapies are seeing rapid development but face many price pressures and regulatory challenges. George Wiker, VP, M+W Group and Kurt Gilson, VP, Western US, Total Facility Solutions, discuss the impact on facility design

Trending Articles

  1. FDA escalates action against Dabur India over systemic data-integrity and cGMP failures The US FDA has issued a warning letter to Dabur India following an inspection that identified falsified records, missing laboratory data, inadequate cleaning and process validation and weaknesses in quality-unit oversight, saying the company's response failed to address the systemic nature of the deficiencies
  2. AstraZeneca-BMS $400bn merger could reshape US pharma manufacturing A potential AstraZeneca acquisition of Bristol Myers Squibb would create a near-$400bn pharma giant, combining major oncology portfolios and extensive US manufacturing operations
  3. Ratio Therapeutics raises $70m to expand radiopharmaceutical manufacturing The Series C financing will support clinical development of Ratio’s Ac-225 radiotherapeutic pipeline and expansion of its radiopharmaceutical manufacturing infrastructure
  4. Roller compaction: stable, continuous production for oral solid dosage forms PCI’s David O’Connell examines how dry granulation supports sensitive formulations, improves powder handling and enables the controlled and scalable manufacture of granules for sachets, capsules and tablets
  5. Thermo Fisher Scientific launches new general purpose centrifuges with natural refrigerant cooling New X2 and S2 Series centrifuges combine precise performance with improved sustainability for research, biopharma and clinical laboratories

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Containment
Clean environments: meeting modern drug production challenges

Clean environments: meeting modern drug production challenges

New medicinal therapies are seeing rapid development but face many price pressures and regulatory challenges. George Wiker, VP, M+W Group and Kurt Gilson, VP, Western US, Total Facility Solutions, discuss the impact on facility design
Manufacturing

Total Facility Solutions builds dedicated hygienic fabrication plant

Company will be better positioned to support the high purity piping needs of numerous life science customers
Manufacturing
Edwards cryogenic portfolio now available globally

Edwards cryogenic portfolio now available globally

Bringing cryogenic cooling and vacuum technologies together in one integrated portfolio for customers worldwide
Manufacturing
SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs

SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs

Featuring the well-known EVERIC® lyo coating, EVERIC® lyo & amber is designed for lyophilised, light-sensitive antibody-drug-conjugates (ADCs). It offers reliable light protection at the primary packaging level, already during the fill-and-finish process. EVERIC amber is the first specialty vial for highly light-sensitive medications that simultaneously meets regulatory light transmission requirements in the EU, the U.S., and Japan
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
Portable gas detection in the pharmaceutical sector

Portable gas detection in the pharmaceutical sector

Gas safety is a critical consideration in the pharmaceutical sector. Hazardous gases and airborne contaminants are common by-products of manufacturing processes … and employers must control worker exposure in accordance with relevant legislation and industry standards
Manufacturing
New legal duties for QPs in decentralised manufacturing

New legal duties for QPs in decentralised manufacturing

In this clip, Dr. Peter Gough explains that QPs will be responsible for supervising decentralised activities, conducting regular audits, carrying out periodic on-site visits, confirming GMP compliance to regulatory authorities and notifying changes that may affect quality or safety
Manufacturing
FDA escalates action against Dabur India over systemic data-integrity and cGMP failures

FDA escalates action against Dabur India over systemic data-integrity and cGMP failures

The US FDA has issued a warning letter to Dabur India following an inspection that identified falsified records, missing laboratory data, inadequate cleaning and process validation and weaknesses in quality-unit oversight, saying the company's response failed to address the systemic nature of the deficiencies
Subscribe now